Dr. Cheung receives funding from the Roy and Marjorie Linden Fund and the Joan Fisher and James Rowland Fund.
Rosenwald A, Wright G, Chan WC, et al. . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
Davis RE, Brown KD, Siebenlist U, et al. . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861–1874.
Vitolo U, Witzig TE, Gascoyne RD, et al. . ROBUST: first report of phase III randomized study of lenalidomide/RCHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol 2019;37(Suppl 2):36–37.
Younes A, Sehn LH, Johnson P, et al. . Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37:1285–1295.
Leonard JP, Kolibaba KS, Reeves JA, et al. . Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 2017;35:3538–3546.
Maurer MJ, Ghesquières H, Link BK, et al. . Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol 2018;36:1603–1610.
Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol 2018;181:495–504.
Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2010.
Hay K, Lee B, Goktepe O, et al. . Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2016;57:276–282.
Camus V, Dubois S, Jardin F, et al. . Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study. Leuk Lymphoma 2019;60:839–841.
Elliss-Brookes L, McPhail S, Ives A, et al. . Routes to diagnosis for cancer—determining the patient journey using multiple routine data sets. Br J Cancer 2012;107:1220–1226.
Kane E, Howell D, Smith A, et al. . Emergency admission and survival from aggressive non-Hodgkin lymphoma: a report from the UK’s population-based Haematological Malignancy Research Network. Eur J Cancer 2017;78:53–60.
Nikonova A, Guirguis HR, Buckstein R, et al. . Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival. Br J Haematol 2015;168:492–500.
Ruan J, Martin P, Furman RR, et al. . Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
Offner F, Samoilova O, Osmanov E, et al. . Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 2015;126:1893–1901.
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. . Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:5058–5066.
Nowakowski GS, LaPlant B, Macon WR, et al. . Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 2015;33:251–257.
Wilson WH, Young RM, Schmitz R, et al. . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922–926.
Castellino A, Chiappella A, LaPlant BR, et al. . Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J 2018;8:108.
Nowakowski G, Chiappella A, Hong F, et al. . Potential factors that impact lenalidomide/R-CHOP efficacy in previously untreated diffuse large B-cell lymphoma in the ROBUST and ECOG-ACRIN 1412 studies [abstract]. Blood 2019;134(Suppl 1):4092. Abstract 626.
Tao L, Foran JM, Clarke CA, et al. . Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood 2014;123:3553–3562.
Smith A, Crouch S, Howell D, et al. . Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol 2015;39:1103–1112.
Le Guyader-Peyrou S, Orazio S, Dejardin O, et al. . Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? Haematologica 2017;102:584–592.
Boslooper K, Hoogendoorn M, van Roon EN, et al. . No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status. Cancer Epidemiol 2017;48:110–116.
Vetterlein MW, Löppenberg B, Karabon P, et al. . Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer 2017;123:3241–3252.